DŽDenisa Janíčková Žďárská

Denisa Janíčková Žďárská

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denisa Janíčková Žďárská has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of Individualized Glycemic Excursions during a Standardized Bout of Hypoglycemia-Inducing Exercise and Subsequent Hypoglycemia Treatment—A Pilot Study

    by Jan Brož, Matthew D. Campbell, Jana Urbanová, Marisa A. Nunes, Ludmila Brunerová, Dario Rahelić, Denisa Janíčková Žďárská, Arian Taniwall, Marek Brabec, Vojtěch Berka, et al.

    The glycemic response to ingested glucose for the treatment of hypoglycemia following exercise in type 1 diabetes patients has never been studied. Therefore, we aimed to characterize glucose dynamics during a standardized bout of hypoglycemia-inducing exercise and the subsequent hypoglycemia treatment with the oral ingestion of glucose. Ten male patients with type 1 diabetes performed a standardized bout of cycling exercise using an electrically braked ergometer at a target heart rate (THR) of 50% of the individual heart rate reserve, determined using the Karvonen equation. Exercise was terminated when hypoglycemia was reached, followed by immediate hypoglycemia treatment with the oral ingestion of 20 g of glucose. Arterialized blood glucose (ABG) levels were monitored at 5 min intervals during exercise and for 60 min during recovery. During exercise, ABG decreased at a mean rate of 0.11 ± 0.03 mmol/L·min−1 (minimum: 0.07, maximum: 0.17 mmol/L·min−1). During recovery, ABG increased at a mean rate of 0.13 ± 0.05 mmol/L·min−1 (minimum: 0.06, maximum: 0.19 mmol/L·min−1). Moreover, 20 g of glucose maintained recovery from hypoglycemia throughout the 60 min postexercise observation window.


  • Open Access

    Analysis of Postprandial Glycemia in Relation to Metabolic Compensation and Other Observed Parameters of Outpatients with Type 2 Diabetes Mellitus in the Czech Republic

    by Denisa Janíčková Žďárská, Martin Hill, Milan Kvapil, Pavlína Piťhová, Jan Brož

    The goal of the study was to determine the level of metabolic compensation expressed by glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose as determined after a standardized breakfast; further, to evaluate interrelationships between the studied parameters and postprandial glucose levels.


    • 1 September 2014
      • Vol. 60  (9) , 712-9

    [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].

    by Denisa Janíčková Zďarská, Jan Brož, Bohumila Křivská, Zdeněk Rušavý, Milan Kvapil

    To evaluate the safety and efficacy of basal insulin glargine using a basal-bolus regimen in a common clinical practice setting in the Czech Republic. The LINDA project was a non-interventional, multicenter (n = 255), national, observational project. A total of 4,998 patients with Type 1 and 2 diabetes mellitus (T1DM, T2DM) with predominantly insulin therapy (99,7 %), after switch on insulin glargine at basal-bolus regimen, were enrolled in this project. The patients were followed up for 6 months after initiation of the therapy with insulin glargine. The primary objective of the project was to investigate the incidence of severe hypoglycemic episodes during the treatment with basal insulin analogue glargine (Lantus®) in a common clinical practice setting. The se-condary endpoints were changes in glycosylated hemoglobin (HbA1c) levels, fasting plasma glucose (FPG), body weight, insulin dose, change of number of hypoglycemic episodes in comparison the previous therapy and the frequency of adverse effects. Severe hypoglycaemia were observed during treatment with insulin glargine at 0.8 % patients. When comparing the incidence of hypoglycemia with the previous therapy, we demonstrated a clinically and statistically significant reduction in their frequencies. The percentage of patients with hypoglycemic episodes (17.6 %), severe hypoglycemia (0.8 %) and severe nocturnal hypoglycemia (0.3 %) over the last month of treatment with insulin glargine using the basal-bolus regimen was consistently lower compared to the last month of treatment before initiation of this therapy (42.5 %, 17.6 %, and 13.8 % of the patients, respectively). In patients with T1DM, the incidence of hypoglycemia decreased from 37.80 ± 15.95 episodes/patient/year to 8.76 ± 4.38 epi-sodes/patient/year (p < 0.001) for all hypoglycemic episodes; from 5.64 ± 3.27 episodes/patient/year to 0.0396 ± 0.012 episodes/patient/year (p < 0.001) for severe hypoglycemia; and from 3.84 ± 2.04 episodes/patient/year to 0.0096 ± 0.003 episodes/patient/year (p < 0.001) for severe nocturnal hypoglycemia. In patients with T2DM, the incidence of hypoglycemia decreased from 12.48 ± 7.57 episodes/patient/year to 1.68 ± 0.78 episodes/patient/year (p < 0.001) for all hypoglycemic episodes; from 2.04 ± 0.94 episodes/patient/year to 0.0132 ± 0.005 episodes/patient/year (p < 0.001) for severe hypoglycemia; and from 1.32 ± 0.77 episodes/patient/year to 0.0048 ± 0.0008 episodes/patient/year (p < 0.001) for severe nocturnal hypoglycemia. A statistically significant improvement in the metabolic control was demonstrated when using insulin glargine. The glycated hemoglobin (HbA1c) decreased from 7.74 ± 1.71 % to 6.43 ± 1.39 % ( -1.31 ± 0.32 %, p < 0.001) in patients with T1DM, and from 8.13 ± 1.56 % to 6.72 ± 1.40 % ( -1.41 ± 0.28 %, p < 0.001) in patients with T2DM. A statistically significant (p < 0.001) increase in the number of patients with HbA1c < 5.4 % was further demonstrated. The decrease in fasting blood glucose (FBG) and 6-point blood sugar profile was also statistically significant in both types of diabetes (p < 0.001). Changes in therapy and subsequent treatment with insulin glargine were perceived positively by both physicians and patients. In the common clinical practice setting, the initiation of treatment with insulin glargine using the basal-bolus regime in patients with previous insulin therapy resulted in a reduction in the incidence of hypoglycemic events, including severe hypoglycemia and severe nocturnal hypoglycemia, and improved metabolic control in patients with diabetes (reduced glycated hemoglobin, fasting glucose values and 6-point blood glucose profile). Greater satisfaction with the current treatment was reported by both patients and physicians.Key words: basal-bolus regimen - diabetes mellitus - insulin glargine - observational project.

  • Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study

    by Denisa Janickova Zdarska, Milan Kvapil, Zdenek Rusavy, Michal Krcma, Jan Broz, Bohumila Krivska, Pavla Kadlecova

    Glucose variability combined with glycosylated hemoglobin (HbA1c) assessments more reliably represents the level of glycemic control. The study was aimed to compare blood glucose variability with insulin glargine vs. neutral protamine Hagedorn (NPH) in patients with type 2 diabetes mellitus using a continuous glucose-monitoring system (CGMS), in patients treated with basal insulin using stable dose of oral antidiabetic agents and HbA1c in the range of 4.5–8.0 % International Federation of Clinical Chemistry (IFCC) units. [6.2–9.4 % Diabetes Control and Complications Trial (DCCT) units]. This was a multicenter, prospective, open-label, single-arm study in patients (N = 116) treated for ≥ 2 months with NPH and metformin combined with sulfonylurea or glinide. Glucose variability was measured after a 4-week NPH treatment phase and after a subsequent 12-week glargine treatment phase using CGMS. Based on 72-hour CGMS, glucose variability was assessed by area under the curve [AUC (mmol/L · h)]. Differences (glargine–NPH) in AUC within 24 h in the glucose ranges of ≤ 3.3, ≤ 3.9, 7.5–3.9 (margins excluding), ≥ 7.5, ≥ 10, and ≥ 15 mmol/L were evaluated. Circadian fluctuation of glucose was assessed by M-value (log-transformation of the deviation from an arbitrary standard). AUCs of glucose in the lowest ranges (≤ 3.3 and ≤ 3.9 mmol/L) did not change significantly after treatment with glargine. Those in the higher ranges (≥ 7.5, ≥ 10, and ≥ 15 mmol/L) were significantly lower (p p p As monitored by CGMS, switching from NPH to glargine with active titration shifted glucose from abnormally high to normal levels with reduced fluctuation and without increased risk of hypoglycemia. Der Grad der Blutzucker Kontrolle wird am Verlässlichsten durch die Kombination der Messung der Glukose Variabilität mit den HbA1c Messungen repräsentiert. Die vorliegende Studie hatte das Ziel, die Blutzucker Variabilität unter Insulin Glargin Therapie mit der unter NPH Insulin bei Patienten mit Typ 2 Diabetes mellitus zu vergleichen. Zur Messung der Variabilität wurde ein kontinuierliches Glukose Monitoring System (KGMS) verwendet. Untersucht wurden Patienten mit einer Therapie mit basalem Insulin und einer gleichbleibenden Dosis von oralen Antidiabetika, die ein HbA1c zwischen 4,5–8,0 % IFCC (6,2–9,4 % DCCT) hatten. Es handelt sich um eine Multicenter prospektive, offene, einarmige Studie an 116 Patienten, die mehr als 2 Monate mit NPH Insulin und Metformin, kombiniert mit Sulfonylurea oder Glinidin behandelt worden waren. Die Glukose Variabilität wurde nach einer 4 wöchigen Phase einer Therapie mit NPH Insulin und nach einer dieser nachfolgenden 12 wöchigen Phase einer Therapie mit Glargin mittels KGMS gemessen, wobei die Fläche unter der jeweiligen Kurve [AUC (mmol/L · h)] einer 72-h Periode erhoben wurde. Unterschiede der unter Glarginin erhobenen AUC zu den unter NPH Insulin ehobenen AUC wurden erhoben, wobei von der AUC einer 24 h Periode die Blutzucker Werte in den Bereichen ≤ 3,3, ≤ 3,9, 7,5–3,9 (ohne Extremwerte), ≥ 7,5, ≥ 10, ≥ 15 mmol/L evaluiert wurden. Die zirkadiane Schwankung des Blutzuckers wurde durch den M Wert (Log-Transformation der Abweichung von einem arbiträrem Standard) bestimmt. Die AUC der Blutzucker Werte im niedrigsten Bereich (≤ 3,3, ≤ 3,9 mmol/L) änderte sich nach Therapie mit Glargin nicht signifikant. Die in den höheren Bereichen (≥ 7,5, ≥ 10, ≥ 15, mmol/L) waren nach dem Ende der Glargin Behandlungsphase signifikant niedriger (p p p Diese Studie ist bei ClinicalTrials.gov unter der Nummer NCT00659477 registriert. Entsprechend der mit KGMS erhobenen Ergebnisse bewirkt das Umsteigen von einer Therapie mit NPH Insulin auf Insulin Glargin mit aktiver Titration ein Absinken der Glukose Werte von abnormal hoch in den normalen Bereich mit weniger Schwankungen und ohne erhöhtes Risiko einer Hypoglykämie.


  • The Effect of Ramipril Therapy on Cytokines and Parameters of Incipient Diabetic Nephropathy in Patients with Type 1 Diabetes Mellitus

    by D Janickova Zdarska, E Zavadova, M Kvapil

    We compared the levels of transforming growth factor β1 (TGF-β1), vascular endothelial growth factor (VEGF) and other biochemical parameters in patients with type 1 diabetes mellitus with and without incipient diabetic nephropathy (iDN) and compared them with healthy control subjects. We also measured the effect of 3 and 6 months of ramipril treatment in diabetes patients with iDN. Compared with healthy controls, TGF-β1 levels were increased in both groups of diabetes patients, whereas VEGF was only elevated in patients with iDN. Ramipril did not have a significant effect on TGF-β1 or VEGF levels. We observed a significant decrease in microalbuminuria and cystatin C following ramipril treatment. Increased VEGF levels in patients with iDN suggest a role for this cytokine in the pathogenesis of diabetic nephropathy. Cystatin C would make a suitable marker for the screening and assessment of iDN, and for the evaluation of the therapeutic efficacy of drugs.